These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1585 related articles for article (PubMed ID: 29039088)

  • 1. Evaluating Nanomedicines: Obstacles and Advancements.
    Swierczewska M; Crist RM; McNeil SE
    Methods Mol Biol; 2018; 1682():3-16. PubMed ID: 29039088
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent advances in green nanoparticulate systems for drug delivery: efficient delivery and safety concern.
    Lam PL; Wong WY; Bian Z; Chui CH; Gambari R
    Nanomedicine (Lond); 2017 Feb; 12(4):357-385. PubMed ID: 28078952
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nanotargeted agents: an emerging therapeutic strategy for breast cancer.
    Du M; Ouyang Y; Meng F; Ma Q; Liu H; Zhuang Y; Pang M; Cai T; Cai Y
    Nanomedicine (Lond); 2019 Jul; 14(13):1771-1786. PubMed ID: 31298065
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nanomedical engineering: shaping future nanomedicines.
    Luo D; Carter KA; Lovell JF
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2015; 7(2):169-88. PubMed ID: 25377691
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nano based drug delivery systems: recent developments and future prospects.
    Patra JK; Das G; Fraceto LF; Campos EVR; Rodriguez-Torres MDP; Acosta-Torres LS; Diaz-Torres LA; Grillo R; Swamy MK; Sharma S; Habtemariam S; Shin HS
    J Nanobiotechnology; 2018 Sep; 16(1):71. PubMed ID: 30231877
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of nanoparticles for therapeutics.
    Hall JB; Dobrovolskaia MA; Patri AK; McNeil SE
    Nanomedicine (Lond); 2007 Dec; 2(6):789-803. PubMed ID: 18095846
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combining Nanomedicine and Immunotherapy.
    Shi Y; Lammers T
    Acc Chem Res; 2019 Jun; 52(6):1543-1554. PubMed ID: 31120725
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nanomedicine opportunities for cardiovascular disease with perfluorocarbon nanoparticles.
    Lanza GM; Winter PM; Caruthers SD; Hughes MS; Cyrus T; Marsh JN; Neubauer AM; Partlow KC; Wickline SA
    Nanomedicine (Lond); 2006 Oct; 1(3):321-9. PubMed ID: 17716162
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic efficacy of nanomedicines for prostate cancer: An update.
    Lakshmanan VK
    Investig Clin Urol; 2016 Jan; 57(1):21-9. PubMed ID: 26966723
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and Toxicological Considerations of Nanomedicines: The Future Directions.
    Patel P; Shah J
    Curr Clin Pharmacol; 2017; 12(2):73-82. PubMed ID: 28486906
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting cancer with hyaluronic acid-based nanocarriers: recent advances and translational perspectives.
    Cadete A; Alonso MJ
    Nanomedicine (Lond); 2016 Sep; 11(17):2341-57. PubMed ID: 27526874
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stimulus-responsive targeted nanomicelles for effective cancer therapy.
    Muthu MS; Rajesh CV; Mishra A; Singh S
    Nanomedicine (Lond); 2009 Aug; 4(6):657-67. PubMed ID: 19663594
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insights into Active Targeting of Nanoparticles in Drug Delivery: Advances in Clinical Studies and Design Considerations for Cancer Nanomedicine.
    Pearce AK; O'Reilly RK
    Bioconjug Chem; 2019 Sep; 30(9):2300-2311. PubMed ID: 31441642
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis of nanomedicines by nanohybrids conjugating ginsenosides with auto-targeting and enhanced MRI contrast for liver cancer therapy.
    Zhao X; Wang J; Song Y; Chen X
    Drug Dev Ind Pharm; 2018 Aug; 44(8):1307-1316. PubMed ID: 29527925
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Medical and dental applications of nanomedicines.
    Kavoosi F; Modaresi F; Sanaei M; Rezaei Z
    APMIS; 2018 Oct; 126(10):795-803. PubMed ID: 30264432
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Theranostic nanomedicine.
    Lammers T; Aime S; Hennink WE; Storm G; Kiessling F
    Acc Chem Res; 2011 Oct; 44(10):1029-38. PubMed ID: 21545096
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nanomedicines: Redefining traditional medicine.
    Lu W; Yao J; Zhu X; Qi Y
    Biomed Pharmacother; 2021 Feb; 134():111103. PubMed ID: 33338747
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nanotechnology and glaucoma: a review of the potential implications of glaucoma nanomedicine.
    Kim NJ; Harris A; Gerber A; Tobe LA; Amireskandari A; Huck A; Siesky B
    Br J Ophthalmol; 2014 Apr; 98(4):427-31. PubMed ID: 24246373
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nanomedicines for kidney diseases.
    Williams RM; Jaimes EA; Heller DA
    Kidney Int; 2016 Oct; 90(4):740-5. PubMed ID: 27292222
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted nanomedicines: effective treatment modalities for cancer, AIDS and brain disorders.
    Muthu MS; Singh S
    Nanomedicine (Lond); 2009 Jan; 4(1):105-18. PubMed ID: 19093899
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 80.